We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
FDA has announced it is proceeding to work with Duramed, a subsidiary of Barr Pharmaceuticals, to resolve the remaining policy issues associated with the marketing of Plan B contraception as an OTC drug.
Pfizer has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Evaluation Agency issued a positive opinion recommending marketing authorization of Champix (varenicline), a treatment for smoking cessation.
Indian drugmaker Orchid Chemicals and Pharmaceuticals and U.S.-based Bexel Pharmaceuticals Inc. have reached an understanding by which Orchid would extend its ownership in Bexel from the current 74 percent to 100 percent.
Schering-Plough Corporation announced that the Japan Ministry of Health, Labor and Welfare (MHLW) has approved TEMODAL(R) (temozolomide) Capsules for the treatment of malignant glioma.
Novartis announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion for the use of Glivec (imatinib)[1] as a treatment for the solid tumor dermatofibrosarcoma protuberans (DFSP) and for hematologic malignancy Philadelphia chromosome-positive (Ph+) acute lymphocytic leukemia (ALL).
The Mumbai police have initiated an investigation into the alleged criminal conspiracy and cheating case filed against the multinational company Novartis and its top executives, by the Mumbai-based Wanbury Ltd.
Ranbaxy chief Malvinder Singh and Max Healthcare chairman Analjit Singh said they have reached a settlement on the will of Ranbaxy founder Bhai Mohan Singh and decided to withdraw all cases against each other.
Roche announced that its cancer medicine Tarceva (erlotinib) has received a negative opinion from the European Committee for Medicinal Products for Human Use (CHMP) for use in combination with gemcitabine chemotherapy for the first line treatment of advanced pancreatic cancer, a cancer with an extremely high fatality rate.
Teva Neuroscience announced today the launch of AZILECT (rasagiline tablets), the first, once-daily treatment for Parkinson's disease (PD) now available in pharmacies by prescription only.